Bioequivalence Tests Based on Individual Estimates Using Non-compartmental or Model-Based Analyses: Evaluation of Estimates of Sample Means and Type I Error for Different Designs

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Pharmaceutical Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Mathematics

• Identifiers
  DOI 10.1007/s11095-009-9980-5PMID 19876723PMCID PMC2881952
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance : non-clinical and clinical issues

  2011cited by this paper
• Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications

  2010influential reference
• Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART

  2009cited by this paper
• Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm

  2009cited by this paper
• Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions

  2009cited by this paper
• Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects.

  2008cited by this paper
• A Simple Numerical Approach Towards Improving the Two One‐Sided Test for Average Bioequivalence

  2008cited by this paper
• A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples

  2007cited by this paper
• APPLIED MIXED MODELS IN MEDICINE, 2ND ED.

  2007cited by this paper
• Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX Software

  2007cited by this paper
• Applied Mixed Models in Medicine, Second Edition, by H. Brown and R. Prescott

  2007cited by this paper
• The SAEM algorithm for group comparison tests in longitudinal data analysis based on non‐linear mixed‐effects model

  2007cited by this paper
• Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters

  2007cited by this paper
• Impact of modelling intra‐subject variability on tests based on non‐linear mixed‐effects models in cross‐over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients

  2007influential reference
• Bioequivalence studies in drug development

  2007cited by this paper
• Applied Mixed Models in Medicine: Brown/Applied Mixed Models in Medicine, 2nd Edition

  2006cited by this paper
• The Utility of the Population Approach Applied to Bioequivalence in Patients: Comparison of 2 Formulations of Cyclosporine

  2005cited by this paper
• Evaluation by simulation of tests based on non‐linear mixed‐effects models in pharmacokinetic interaction and bioequivalence cross‐over trials

  2005influential reference
• Unaltered Etanercept Pharmacokinetics With Concurrent Methotrexate in Patients With Rheumatoid Arthritis

  2004cited by this paper
• Statistical Issues in a Modeling Approach to Assessing Bioequivalence or PK Similarity with Presence of Sparsely Sampled Subjects

  2004influential reference
• Coupling a stochastic approximation version of EM with an MCMC procedure

  2004cited by this paper
• Design and Analysis of Bioavailability and Bioequivalence Studies

  2003cited by this paper
• Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications

  2002cited by this paper
• Estimation of rhG-CSF absorption kinetics after subcutaneous administration using a modified Wagner-Nelson method with a nonlinear elimination model.

  2001cited by this paper
• Mixed-Effects Models in S and S-PLUS

  2001influential reference
• Linear Mixed Models for Longitudinal Data

  2001cited by this paper
• Bioequivalent or nonbioequivalent?

  2001cited by this paper
• COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS ( CPMP ) NOTE FOR GUIDANCE ON THE INVESTIGATION OF BIOAVAILABILITY AND BIOEQUIVALENCE

  2001cited by this paper
• Applied Mixed Models in Medicine

  2000influential reference
• Characterization of the highly variable bioavailability of tiludronate in normal volunteers using population pharmacokinetic methodologies

  1999influential reference
• Convergence of a stochastic approximation version of the EM algorithm

  1999cited by this paper
• An unbiased test for the bioequivalence problem

  1997cited by this paper
• A Comparison of the Standard Approach and the NONMEM Approach in the Estimation of Bioavailability in Man

  1997cited by this paper
• Bioequivalence: Individual and Population Compartmental Modeling Compared to the Noncompartmental Approach

  1996cited by this paper
• Bioequivalence trials, intersection-union tests and equivalence confidence sets

  1996cited by this paper
• Bias of two one-sided tests procedures in assessment of bioequivalence.

  1995influential reference
• A note on the delta method

  1992cited by this paper
• Nonlinear mixed effects models for repeated measures data.

  1990cited by this paper
• Application of the NONMEM method to evaluation of the bioavailability of drug products.

  1990influential reference
• A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

  1987cited by this paper
• Nonlinear assessment of phenytoin bioavailability

  1976cited by this paper

• The Finite Absorption Time Concept Guiding Model Informed Drug & Generics Development in Clinical Pharmacology

  2025cites this paper
• Evaluation of model‐integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods

  2024influential citation
• A Bayesian framework for virtual comparative trials and bioequivalence assessments

  2024cites this paper
• Development and comparison of model‐integrated evidence approaches for bioequivalence studies with pharmacokinetic end points

  2024cites this paper
• Evaluation of model‐based bioequivalence approach for single sample pharmacokinetic studies

  2023cites this paper
• Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)

  2022cites this paper
• Simulation Models for Prediction of Bioavailability of Medicinal Drugs—the Interface Between Experiment and Computation

  2022cites this paper
• Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical‐driven balance of population average and variability

  2022cites this paper
• Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies

  2022cites this paper
• Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

  2022cites this paper
• Model‐Informed Drug Development for Long‐Acting Injectable Products: Summary of American College of Clinical Pharmacology Symposium

  2021cites this paper
• New Model–Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse Sampling

  2020cites this paper
• Efficient model-based bioequivalence testing.

  2020cites this paper
• Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies

  2019cites this paper
• Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine

  2018cites this paper
• Design and inference for 3‐stage bioequivalence testing with serial sampling data

  2018cites this paper
• Flexible multivariate nonlinear models for bioequivalence problems

  2017cites this paper
• Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations

  2017cites this paper
• Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers

  2016cites this paper
• Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies

  2016cites this paper
• Compartmental approach to assess bioequivalence compared to the noncompartmental approach.

  2016cites this paper
• Pharmacokinetics in Drug Development

  2016cites this paper
• Role of Pharmacokinetics: Pharmacodynamics in Biosimilar Assessment

  2016cites this paper
• Modeling and Simulation in Bioequivalence

  2016cites this paper
• Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates

  2015cites this paper
• Utilisation et développement de techniques pharmacocinétiques avancées afin d’améliorer le développement de molécules pharmaceutiques

  2015cites this paper
• Statistical Considerations in Assessing Drug–Drug Interactions for Therapeutic Biologics

  2013cites this paper
• The use of pharmacometrics to optimize biosimilar development.

  2013cites this paper
• Novel population pharmacokinetic method compared to the standard noncompartmental approach to assess bioequivalence of iron gluconate formulations.

  2013cites this paper
• How to combine non-compartmental analysis with the population pharmacokinetics? A study of tobacco smoke’s influence on the bioavailability of racemic citalopram in rats

  2013cites this paper
• Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models

  2012cites this paper
• The Use of Nonlinear Mixed Effects Models in Bioequivalence Studies: A Real Data Application

  2012influential citation
• Non‐compartmental estimation of pharmacokinetic parameters for flexible sampling designs

  2012cites this paper
• Population Pharmacokinetic and Pharmacodynamic Model‐Based Comparability Assessment of a Recombinant Human Epoetin Alfa and the Biosimilar HX575

  2012cites this paper
• Analysis of pharmacokinetic similarity of biologics using nonlinear mixed effects modelling

  2012cites this paper
• Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed‐Effects Modeling

  2012cites this paper
• Simultaneous Confidence Bands for Nonlinear Regression Models with Application to Population Pharmacokinetic Analyses

  2011cites this paper
• Model‐based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm

  2011cites this paper
• Pharmacogénétique en Pharmacocinétique de population : tests et sélection de modèles

  2009cites this paper